Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × Alemtuzumab × 90 days × Clear all

Sponsor

Conditions

Wilms Tumor 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Pseudomyxoma Peritonei 1 Neuroblastoma 1 Neoplasms, Germ Cell and Embryonal 1 Melanoma 1 Lymphoma 1 Digestive System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Adenocarcinoma, Clear Cell 1

Interventions

Cyclophosphamide 3 Biopsy 3 Azacitidine 3 Prednisone 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Doxorubicin 2 tislelizumab 1 tazemetostat 1 sodium-iodide symporter 1 selinexor 1 ruxolitinib 1 romidepsin 1 relatlimab 1 pembrolizumab 1 ivarmacitinib 1 gemcitabine-oxaliplatin regimen 1 fludarabine 1 etoposide phosphate 1 duvelisib 1 decitabine and cedazuridine drug combination 1 cemiplimab 1 cc-486 1 belinostat 1 X-Rays 1 Vincristine 1 Spinal Puncture 1 Specimen Handling 1 Salvage Therapy 1 Prednisolone 1 Photons 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡